Signature Receives Extended Patent Protection for its Proteasome-Complex Inhibitors
Signature Diagnostics AG announced today
that the European Patent Office (EPO) has granted a new patent providing
extended protection for drug molecules licensed by the company from the
Technical University of Darmstadt. The new patent (EP 1858913) covers peptide-
mimetics and their use as inhibitors of the human proteasome complex. The
molecules have immediate application in a variety of indications, including
cancer and inflammatory disease. The company is currently seeking cooperation
partners for further development of these proteasome-inhibitor drug candidates.
"This patent further strengthens our strong intellectual property portfolio in
key therapeutic areas such as cancer and inflammation," commented André
Rosenthal, Chief Executive Officer of Signature Diagnostics. "We are committed
to maximizing the patent protection for these drug candidates, as they are
essential value-drivers for the company and its future partners."
(Quelle: OPI, 07.12.2010 Press Release Signature Diagnostics)
Lesen sie hier den ausführlichen Artikel: